D-1006-2019 Class III Terminated
FDA drug recall D-1006-2019 was initiated by Teva Pharmaceuticals USA on Mar 11, 2019 and is designated Class III. Reason for recall: Subpotent Drug. The recall status is terminated (terminated Nov 15, 2019). Affected quantity: 7,081 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2019
- Initiation Date
- Mar 11, 2019
- Termination Date
- Nov 15, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7,081 bottles
Product description
Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100 tablets (10 blister cards of 10 tablets each), Rx only, Manufactured in Israel By: Teva Pharmaceutical Ind. Ltd. Jerusalem, 9777402, Israel, Manufactured for: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0093-3008-93
Reason for recall
Subpotent Drug.
Distribution pattern
Nationwide in the United States.
Code information
Lot #: 25Q002, Exp. 11/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1006-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026